Daily News Podcast

Brain damage, slight benefit seen in epinephrine cardiac arrest


 

Epinephrine provided a slight 30-day survival benefit, but those patients experienced more severe brain damage. Also today, nerve growth factor inhibitor shows phase-3 efficacy in osteoarthritis, National Academies issues a 5-step plan to address infections linked to opioid use disorder, and there may be beneficial class effects of SGLT2 inhibitors, including dapagliflozin. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

Judge Brett Kavanaugh and the ACA
MDedge Cardiology
New guidelines could mean millions more with hypertension
MDedge Cardiology
AHRQ National Guideline Clearinghouse shutting down
MDedge Cardiology
Less documentation highlights new Medicare fee proposal
MDedge Cardiology
Too many antibiotics prescribed in urgent care
MDedge Cardiology
CREDENCE canagliflozin trial halted because of efficacy
MDedge Cardiology
Managing HIV with diabetes
MDedge Cardiology
Telemedicine payment expansion?
MDedge Cardiology
Epinephrine for cardiac arrest: Better survival, more brain damage
MDedge Cardiology
Bundle pay plan didn’t save money
MDedge Cardiology